Perspective Therapeutics, Inc. key statistics and ratios
In fiscal 2023, Perspective Therapeutics, Inc. had return on equity of -71.6%, an operating margin of -2855.0%, debt equal to 2.4% of equity and a current ratio of 1.07. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Dec 2022 | 2023Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 22.1% | 13.9% | 3.3% | −4.7% | 3.6% | 2.7% | 17.6% | 31.1% | 41.7% | 52.9% | 50.9% | — | 100.0% |
| Operating margin | −56.6% | −71.0% | −89.9% | −108.7% | −94.2% | −106.6% | −132.5% | −113.6% | −71.8% | −35.9% | −34.3% | — | <−999% |
| Net margin | −54.3% | −68.8% | −85.2% | −141.2% | −79.9% | −98.8% | −129.4% | −113.1% | −70.3% | −35.6% | −33.7% | — | <−999% |
| Free-cash-flow margin | −48.8% | −49.4% | −67.7% | −77.0% | −79.4% | −91.5% | −131.5% | −102.1% | −75.1% | −40.4% | −32.0% | — | <−999% |
| Return on equity | −44.0% | −56.9% | −69.0% | −40.6% | −16.5% | −25.3% | −45.6% | −85.7% | −80.9% | −51.4% | −9.3% | — | −71.6% |
| Return on assets | −36.0% | −45.3% | −53.0% | −35.5% | −14.9% | −22.9% | −40.6% | −67.9% | −61.0% | −38.0% | −8.6% | — | −59.6% |
| Asset turnover | 0.66 | 0.66 | 0.62 | 0.25 | 0.19 | 0.23 | 0.31 | 0.60 | 0.87 | 1.07 | 0.25 | — | 0.02 |
| Current ratio | 5.45 | 6.37 | 5.60 | 16.65 | 14.95 | 12.46 | 9.30 | 2.97 | 6.53 | 3.50 | 37.37 | 17.07 | 1.07 |
| Debt to equity | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% |
| Interest cover (operating income ÷ interest) | — | — | n/m | n/m | n/m | n/m | — | — | — | — | — | — | n/m |
| R&D as % of revenue | 18.7% | 15.4% | 13.9% | 15.9% | 13.4% | 11.1% | 20.3% | 29.5% | 20.2% | 11.6% | 14.2% | — | >999% |
| Capital spending as % of revenue | 2.6% | 1.1% | 0.1% | 0.5% | 2.9% | 10.0% | 11.5% | 5.7% | 6.1% | 2.8% | 3.8% | — | 74.8% |
| Quarter | 2022 Q1Mar 2022 | 2022 Q2Jun 2022 | 2022 Q3Sept 2022 | 2022 Q4Dec 2022 | 2023 Q1Mar 2023 | 2023 Q2Jun 2023 | 2023 Q3Sept 2023 | 2023 Q4Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 49.5% | 37.0% | 24.1% | −22.6% | 23.6% | 11.9% | 33.8% | — |
| Operating margin | −47.3% | −84.1% | −245.1% | −77.0% | −473.1% | −467.1% | −446.2% | — |
| Net margin | −46.3% | −83.0% | −236.9% | −178.0% | −18.0% | −531.9% | −474.0% | — |
| Free-cash-flow margin | −49.8% | −119.6% | −107.9% | −238.9% | −481.0% | −413.2% | −473.1% | — |
| Current ratio | 32.08 | 26.18 | 14.38 | 17.07 | 5.60 | 3.72 | 2.67 | 1.07 |
| Debt to equity | — | — | — | 0.0% | 1.5% | 1.6% | 1.8% | 2.3% |
| R&D as % of revenue | 18.9% | 31.8% | 41.2% | −13.1% | 160.4% | 257.2% | 254.1% | — |
Moat
Weak moat
How hard Perspective Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -30.1% of total assets over 10 years.
- Pricing power 4 / 20
Gross margin has been a median 32.3%, moving by 28.9 percentage points (standard deviation) across 10 years.
- Durability 10 / 20
Operating margin has been a median -100.9%; its worst year was -2855.0%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 10 years, at a median -82.0% of revenue.
- Discipline 4 / 20
The diluted share count rose 1279.1% over five years; stock-based pay has been a median 6.5% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (18 before it).
Compare with peers
More: Biotechnology stocks compared, Health Care sector, rankings of US companies